| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/0002-9378(87)90170-0 |
| P8608 | Fatcat ID | release_vjbvsz5lxzgf5mqooguj6regdi |
| P698 | PubMed publication ID | 3555093 |
| P2093 | author name string | Fraser D | |
| Whitehead MI | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | estrogen | Q277954 |
| P304 | page(s) | 1313-1322 | |
| P577 | publication date | 1987-05-01 | |
| P1433 | published in | American Journal of Obstetrics and Gynecology | Q4744256 |
| P1476 | title | Controversies concerning the safety of estrogen replacement therapy | |
| P478 | volume | 156 |
| Q37070505 | 9 Oestrogen therapy and cardiovascular disease: Do the benefits outweigh the risks? |
| Q37974171 | A risk-benefit assessment of estrogen therapy in postmenopausal women |
| Q35055685 | Alternative strategies for prevention of postmenopausal osteoporosis. |
| Q53972828 | Cardiovascular risk factors during sequentially combined 17 beta oestradiol and dydrogesterone (Femoston); results from a one-year study in postmenopausal women. |
| Q43263960 | Clinical pharmacology and therapeutics |
| Q74148247 | Continuous-combined treatment of the menopause with combinations of oestradiol valerate and dienogest - a dose-ranging study |
| Q41498790 | Controversies surrounding estrogen use in postmenopausal women |
| Q43547899 | Estriol: a weak estrogen or a different hormone? |
| Q37917064 | Estrogen therapy during menopause. Practical treatment recommendations |
| Q39490443 | HRT and osteoporosis |
| Q40609583 | Herbal extract prevents bone loss in ovariectomized rats |
| Q34370222 | Hormone replacement therapy and breast cancer, endometrial cancer and cardiovascular disease: risks and benefits |
| Q40877118 | Hormone replacement therapy and cancer |
| Q24201543 | Hormone therapy in postmenopausal women and risk of endometrial hyperplasia |
| Q24241713 | Hormone therapy in postmenopausal women and risk of endometrial hyperplasia |
| Q24246573 | Hormone therapy in postmenopausal women and risk of endometrial hyperplasia |
| Q67749359 | Intranasal administration of estradiol in combination with progesterone to oophorectomized women: a pilot study |
| Q36271670 | Lasofoxifene (CP-336,156), a novel selective estrogen receptor modulator, in preclinical studies |
| Q37942117 | Long-term adjuvant tamoxifen therapy for breast cancer |
| Q70199870 | Management of osteoporosis |
| Q43903240 | Neuroendocrine and clinical effects of transdermal 17β-estradiol in postmenopausal women |
| Q40877161 | Oestrogens and atherosclerotic vascular disease--lipid factors |
| Q69918804 | Patch up the menopause |
| Q39495910 | Percutaneous and transdermal oestrogen replacement therapy |
| Q45265150 | Phytoestrogen alpha-zearalanol inhibits atherogenesis and improves lipid profile in ovariectomized cholesterol-fed rabbits |
| Q40864441 | Postmenopausal hormone replacement: are two hormones better than one? |
| Q36109111 | Progestogen safety and tolerance in hormonal replacement therapy |
| Q33828714 | Recommendations for estrogen and progestin replacement in the climacteric and postmenopause. European Progestin Club |
| Q34549695 | Reproductive toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in female rats |
| Q69972760 | Serum and bile lipid levels in a postmenopausal woman after percutaneous and oral natural estrogens |
| Q73937722 | Strategies to reduce the incidence of endometrial cancer in postmenopausal women |
| Q37943168 | The menopause in perspective. From potions to patches |
| Q40892229 | The menopause: health implications and clinical management |
| Q44245583 | The optimal dose of oral norethindrone acetate for addition to transdermal estradiol: a multicenter study. |
Search more.